EA200600626A1 - Композиция и лекарственная форма продолжительного выделения леводопы - Google Patents
Композиция и лекарственная форма продолжительного выделения леводопыInfo
- Publication number
- EA200600626A1 EA200600626A1 EA200600626A EA200600626A EA200600626A1 EA 200600626 A1 EA200600626 A1 EA 200600626A1 EA 200600626 A EA200600626 A EA 200600626A EA 200600626 A EA200600626 A EA 200600626A EA 200600626 A1 EA200600626 A1 EA 200600626A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- longiodopa
- ducted
- composition
- low
- medication form
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 6
- 229960003638 dopamine Drugs 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 2
- 208000012661 Dyskinesia Diseases 0.000 abstract 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 229960004502 levodopa Drugs 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51297303P | 2003-10-20 | 2003-10-20 | |
| PCT/US2004/034121 WO2005042101A1 (en) | 2003-10-20 | 2004-10-14 | Composition and dosage form for sustained effect of levodopa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200600626A1 true EA200600626A1 (ru) | 2007-02-27 |
Family
ID=34549241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200600626A EA200600626A1 (ru) | 2003-10-20 | 2004-10-14 | Композиция и лекарственная форма продолжительного выделения леводопы |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050113452A1 (enExample) |
| EP (1) | EP1675651A1 (enExample) |
| JP (1) | JP2007509146A (enExample) |
| KR (2) | KR20080109101A (enExample) |
| AU (1) | AU2004285436C1 (enExample) |
| CA (1) | CA2553156A1 (enExample) |
| EA (1) | EA200600626A1 (enExample) |
| IL (1) | IL174591A0 (enExample) |
| MX (1) | MXPA06004327A (enExample) |
| NZ (1) | NZ546662A (enExample) |
| WO (1) | WO2005042101A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7674480B2 (en) | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| DE10214188B4 (de) | 2002-03-28 | 2005-08-25 | Siemens Ag | Verfahren zur gesicherten Übertragung von Daten, insbesondere zur Übertragung über eine Luftschnittstelle |
| MX2007001058A (es) * | 2004-07-26 | 2007-04-16 | Teva Pharma | Formas de dosificacion con tableta nucleo recubierta entericamente. |
| US7780981B2 (en) | 2004-09-13 | 2010-08-24 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| WO2007011701A1 (en) * | 2005-07-15 | 2007-01-25 | Transform Pharmaceuticals, Inc. | Novel hydrochloride salts of levodopa |
| US20070178149A1 (en) * | 2005-11-07 | 2007-08-02 | Moshe Flashner-Barak | Levodopa compositions |
| WO2007138086A1 (en) * | 2006-05-31 | 2007-12-06 | Solvay Pharmaceuticals Gmbh | Long term 24 hour intestinal administration of levodopa/carbidopa |
| US8765178B2 (en) | 2006-07-19 | 2014-07-01 | Watson Laboratories, Inc. | Controlled release formulations and associated methods |
| KR101122469B1 (ko) * | 2007-04-02 | 2012-07-12 | 파킨슨즈 인스티튜트 | 처치 치료의 부작용을 감소시키기 위한 방법 및 조성물 |
| CA2841785A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
| JP2018511355A (ja) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 薬剤送達方法及びシステム |
| US10679516B2 (en) | 2015-03-12 | 2020-06-09 | Morningside Venture Investments Limited | Craving input and support system |
| WO2018129304A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| CA3101966A1 (en) | 2018-05-29 | 2019-12-05 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| MA54245A (fr) | 2018-11-16 | 2022-02-23 | Morningside Venture Investments Ltd | Système d'administration transdermique de médicaments à régulation thermique |
| IT202000019303A1 (it) * | 2020-08-05 | 2022-02-05 | Univ Degli Studi Di Brescia | Analoghi strutturali del metilfenidato come agenti disease-modifying della malattia di parkinson |
| EP4316482A1 (en) * | 2022-08-01 | 2024-02-07 | 4P-Pharma | Levodopa for preventing addiction |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2042520T3 (es) * | 1986-06-10 | 1993-12-16 | Chiesi Farma Spa | Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo. |
| US4983400A (en) * | 1986-06-16 | 1991-01-08 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| US4832957A (en) * | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| ZA889189B (en) * | 1986-06-16 | 1989-08-30 | Merck & Co Inc | Controlled release combination of carbidopa/levodopa |
| US4716246A (en) * | 1986-08-22 | 1987-12-29 | Merck & Co., Inc. | Process for L-dopa |
| US5994392A (en) * | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
| US5041430A (en) * | 1989-09-18 | 1991-08-20 | Du Pont Mereck Pharmaceutical Company | Oral anticoagulant/platelet inhibitor low dose formulation |
| US5607969A (en) * | 1992-12-24 | 1997-03-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-DOPA ethyl ester to treat Parkinson's disease |
| US6117453A (en) * | 1995-04-14 | 2000-09-12 | Pharma Pass | Solid compositions containing polyethylene oxide and an active ingredient |
| US5840756A (en) * | 1995-07-21 | 1998-11-24 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition of L-DOPA ester |
| US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
| US6797283B1 (en) * | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
| US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| JP2004501190A (ja) * | 2000-06-23 | 2004-01-15 | テバ ファーマシューティカル インダストリーズ リミティド | 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形 |
| JP4426286B2 (ja) * | 2001-07-10 | 2010-03-03 | テバ ファーマシューティカル インダストリーズ リミティド | ０次、０次−二相性、上昇型又は下降型薬物放出のための薬物送達システム |
| US20040052843A1 (en) * | 2001-12-24 | 2004-03-18 | Lerner E. Itzhak | Controlled release dosage forms |
| NZ552513A (en) * | 2001-12-24 | 2008-08-29 | Teva Pharma | Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it |
-
2004
- 2004-10-14 MX MXPA06004327A patent/MXPA06004327A/es unknown
- 2004-10-14 AU AU2004285436A patent/AU2004285436C1/en not_active Ceased
- 2004-10-14 NZ NZ546662A patent/NZ546662A/en unknown
- 2004-10-14 WO PCT/US2004/034121 patent/WO2005042101A1/en not_active Ceased
- 2004-10-14 KR KR1020087029777A patent/KR20080109101A/ko not_active Ceased
- 2004-10-14 US US10/966,090 patent/US20050113452A1/en not_active Abandoned
- 2004-10-14 KR KR1020067009822A patent/KR100894465B1/ko not_active Expired - Fee Related
- 2004-10-14 JP JP2006536678A patent/JP2007509146A/ja active Pending
- 2004-10-14 EA EA200600626A patent/EA200600626A1/ru unknown
- 2004-10-14 EP EP04795307A patent/EP1675651A1/en not_active Withdrawn
- 2004-10-14 CA CA002553156A patent/CA2553156A1/en not_active Abandoned
-
2006
- 2006-03-27 IL IL174591A patent/IL174591A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20050113452A1 (en) | 2005-05-26 |
| KR20080109101A (ko) | 2008-12-16 |
| AU2004285436B2 (en) | 2009-01-08 |
| AU2004285436C1 (en) | 2009-07-16 |
| WO2005042101A1 (en) | 2005-05-12 |
| NZ546662A (en) | 2009-03-31 |
| JP2007509146A (ja) | 2007-04-12 |
| CA2553156A1 (en) | 2005-05-12 |
| MXPA06004327A (es) | 2007-01-26 |
| KR20070085032A (ko) | 2007-08-27 |
| WO2005042101A8 (en) | 2006-10-19 |
| KR100894465B1 (ko) | 2009-04-22 |
| IL174591A0 (en) | 2006-08-20 |
| EP1675651A1 (en) | 2006-07-05 |
| AU2004285436A1 (en) | 2005-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200600626A1 (ru) | Композиция и лекарственная форма продолжительного выделения леводопы | |
| MX2009012093A (es) | Nuevos peptidos inhibidores de la replicacion del virus de la hepatitis c. | |
| JO3598B1 (ar) | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني | |
| BRPI0813699A2 (pt) | Formulações de proteína de fusão glp-1-fc | |
| WO2008092006A3 (en) | Antimicrobial compositions | |
| EA201100305A1 (ru) | Лечение респираторных заболеваний | |
| TW200512195A (en) | Benzamide 2-hydroxy-3-diaminoalkanes | |
| MY148690A (en) | Novel macrocyclic inhibitors of hepatitis c virus replication | |
| EA201001669A1 (ru) | Замещенные пиримидин-5-карбоксамиды 281 | |
| MY151295A (en) | Pyrimidyl indoline compound | |
| NZ578928A (en) | Methods to increase mobility of hematopoietic stem cells by use of a lipopeptide compound and treatment of associated diseases | |
| TW200505418A (en) | Phenacyl 2-hydroxy-3-diaminoalkanes | |
| EA201200968A1 (ru) | Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин | |
| MY147643A (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder | |
| CL2007000789A1 (es) | Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer. | |
| WO2007112272A3 (en) | Formulations of low dose diclofenac and beta-cyclodextrin | |
| MY143568A (en) | 11b-hsd1 inhibitors for the treatment of diabetes | |
| EP1781277A4 (en) | COMBINATION PREPARATION | |
| TW200639159A (en) | Treatment of pain | |
| WO2007056264A3 (en) | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally | |
| CR10410A (es) | Carboxamidas sustituidas. | |
| SE0004101D0 (sv) | New use | |
| WO2007056263A3 (en) | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously | |
| MXPA05008711A (es) | Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico. | |
| AR039162A1 (es) | Formulaciones de venlafaxina de liberacion extendida |